Combination of α‐interferon with lamivudine reduces viral breakthrough during long‐term therapy
Myoung Kuk Jang, Dong Jin Suh(Daehang Hospital), Han Chu Lee(Asan Medical Center), Young–Hwa Chung(Jeju National University Hospital), In‐Sook Kim(Frederick National Laboratory for Cancer Research), Neung Hwa Park(Ulsan College), Jeong‐Ah Kim(Ulsan College), Soo Hyung Ryu(Ulsan College), Jung Woo Shin(Ulsan College), Yung Sang Lee(The University of Texas at Dallas), M.H. Choi(Ulsan College)
Cited by 15
Related Papers
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine
|Journal of Lipid Research|2007|595
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
|European Journal of Cancer|2011|573
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice
|Carcinogenesis|2006|359